Ki-67 and p53 protein production in the development of verrucous carcinoma

Introduction. Oral verrucous carcinoma is classified as a well-differentiated squamous cell carcinoma. Histologically, it is characterized by hyperkeratosis, epithelial hyperplasia, preservation of basal membrane integrity, and chronic inflammation in the lamina propria of the mucosa. The development of verrucous carcinoma typically begins with verrucous hyperplasia, which exhibits a histological pattern similar to that of verrucous carcinoma. For a more accurate diagnosis, immunohistochemical methods are used. The proliferative activity of cells is assessed using the Ki-67 marker. Alterations in tumor cell apoptosis are studied by examining the p53 protein in its two forms: wild-type (WTp53) and mutant-type (MTp53). The paper aimed to evaluate immunoreactive cells for Ki-67 and p53 proteins in verrucous hyperplasia and verrucous carcinoma. Materials and methods. To investigate verrucous hyperplasia and verrucous carcinoma, we examined oral mucosal biopsy samples obtained from patients with a preliminary clinical diagnosis of leukoplakia. A total of 27 cases were analyzed, including 18 cases of verrucous hyperplasia (66.6%) and 9 cases of verrucous carcinoma (33.3%). Proliferative activity was assessed using anti-Ki-67 antibodies. For p53 analysis, two antibody clones were used: DO-7, which detects both wild- and mutant-type proteins, and Y5, which specifically detects the mutant form. Results. Immunoreactive cells for WTp53 protein accounted for 19.4% (16.40; 21.10) in verrucous hyperplasia compared to 26.0% (25.70; 27.10) in verrucous carcinoma, with higher nuclear staining intensity observed in the latter. For MTp53 protein, the values were 5.1% (2.90; 5.60) in verrucous hyperplasia and 28.1% (27.10; 29.90) in verrucous carcinoma. The presence of isolated immunopositive cells in the verrucous hyperplasia group may be interpreted as early genomic alterations and the onset of neoplasia. Conclusion. MTp53 protein can be used for the differential diagnosis of verrucous hyperplasia and verrucous carcinoma, as the presence of immunopositive cells indicates genomic mutations in oral mucosal epithelial cells. Keywords: verrucous carcinoma, p53, MTp53, WTp53

Authors

Publication Details

Journal
CLINICAL AND EXPERIMENTAL MORPHOLOGY
Published
2025-01-01
DOI
https://doi.org/10.31088/cem2025.14.3.42-48
Primary Topic
Oral Health Pathology and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Ki-67 and p53 protein production in the development of verrucous carcinoma

О Ф Рабинович, A A Ivina, И И Бабиченко, Rabinovich Im et al.
CLINICAL AND EXPERIMENTAL MORPHOLOGY
Oral Health Pathology and Treatment
article

Ki-67 and p53 protein production in the development of verrucous carcinoma

О Ф Рабинович, A A Ivina, И И Бабиченко, Rabinovich Im, D.R. Familia Frias, Yu.O. Tigay
article en

Abstract

Introduction. Oral verrucous carcinoma is classified as a well-differentiated squamous cell carcinoma. Histologically, it is characterized by hyperkeratosis, epithelial hyperplasia, preservation of basal membrane integrity, and chronic inflammation in the lamina propria of the mucosa. The development of verrucous carcinoma typically begins with verrucous hyperplasia, which exhibits a histological pattern similar to that of verrucous carcinoma. For a more accurate diagnosis, immunohistochemical methods are used. The proliferative activity of cells is assessed using the Ki-67 marker. Alterations in tumor cell apoptosis are studied by examining the p53 protein in its two forms: wild-type (WTp53) and mutant-type (MTp53). The paper aimed to evaluate immunoreactive cells for Ki-67 and p53 proteins in verrucous hyperplasia and verrucous carcinoma. Materials and methods. To investigate verrucous hyperplasia and verrucous carcinoma, we examined oral mucosal biopsy samples obtained from patients with a preliminary clinical diagnosis of leukoplakia. A total of 27 cases were analyzed, including 18 cases of verrucous hyperplasia (66.6%) and 9 cases of verrucous carcinoma (33.3%). Proliferative activity was assessed using anti-Ki-67 antibodies. For p53 analysis, two antibody clones were used: DO-7, which detects both wild- and mutant-type proteins, and Y5, which specifically detects the mutant form. Results. Immunoreactive cells for WTp53 protein accounted for 19.4% (16.40; 21.10) in verrucous hyperplasia compared to 26.0% (25.70; 27.10) in verrucous carcinoma, with higher nuclear staining intensity observed in the latter. For MTp53 protein, the values were 5.1% (2.90; 5.60) in verrucous hyperplasia and 28.1% (27.10; 29.90) in verrucous carcinoma. The presence of isolated immunopositive cells in the verrucous hyperplasia group may be interpreted as early genomic alterations and the onset of neoplasia. Conclusion. MTp53 protein can be used for the differential diagnosis of verrucous hyperplasia and verrucous carcinoma, as the presence of immunopositive cells indicates genomic mutations in oral mucosal epithelial cells. Keywords: verrucous carcinoma, p53, MTp53, WTp53

CLINICAL AND EXPERIMENTAL MORPHOLOGYVol. 14(3)
Openalex Percentile: Top 87%
Oral Health Pathology and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.